GlassScriptPhysician profile
Pedro Pablo Torres
NPI 1699271270
$10,077.12
in general payments reported to CMS, 2019-2025
23 companies · $5,433 in 2025
The $5,433 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $550 · 2023: $1,238 · 2024: $2,733 · 2025: $5,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,353 · Travel and Lodging: $3,378 · Education: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,352.54 |
| Travel and Lodging | $3,378.47 |
| Education | $672.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $4,292.49 | 2023-2025 | Carto 3, Visitag Surpoint External Processing Unit, Nuvision Ice Catheter |
| Medical Device Business Services, INC. | $1,315.19 | 2024 | Carto 3 |
| Abiomed | $769.42 | 2023-2025 | Impella |
| Inari Medical, INC. | $686.06 | 2022-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic, INC. | $569.82 | 2022-2025 | Cardioblate Cryoflex, Micra, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $525.10 | 2023-2025 | Ensite, Ensite Precision, Na |
| Cvrx, INC. | $297.55 | 2024 | Barostim Neo System |
| Ge Healthcare | $219.09 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $195.75 | 2022-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $180.35 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $141.92 | 2023-2025 | Farxiga |
| Novo Nordisk INC | $141.19 | 2021-2024 | Ozempic |
| Actelion Pharmaceuticals US, INC. | $138.04 | 2024-2025 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $136.46 | 2025 | |
| Merck Sharp & Dohme LLC | $83.86 | 2024-2025 | Winrevair, Verquvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $81.95 | 2024-2025 | Repatha |
| Boston Scientific Corporation | $67.27 | 2024-2025 | Watchman Flx, Watchman |
| United Therapeutics Corporation | $61.21 | 2024-2025 | Tyvaso, Remodulin |
| W. L. Gore & Associates, INC. | $56.49 | 2022 | |
| Bridgebio Pharma, INC. | $48.28 | 2025 | Attruby |
| Pfizer INC. | $25.09 | 2024 | |
| Scpharmaceuticals INC. | $24.66 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.